Clinical Trials Logo

Stage III NSCLC clinical trials

View clinical trials related to Stage III NSCLC.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05740943 Recruiting - Surgery Clinical Trials

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Start date: March 15, 2023
Phase: Phase 2
Study type: Interventional

A prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical feasibility of dynamic ctDNA and multidisciplinary assessment in guiding local treatments.

NCT ID: NCT05631574 Recruiting - Colorectal Cancer Clinical Trials

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Start date: January 12, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

NCT ID: NCT05403385 Recruiting - Metastatic NSCLC Clinical Trials

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Start date: August 26, 2022
Phase: Phase 2
Study type: Interventional

Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving specific first line treatments for Stage 3 or metastatic non-small cell lung cancer. Part 2 compares the efficacy of inupadenant to placebo when both are combined with carboplatin and pemetrexed for patients that progressed after receiving the same first line treatments for Stage 3 or metastatic non-small cell lung cancer.

NCT ID: NCT04636593 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

Previous clinical studies showed there is a potential value of EGFR-TKI in local advanced EGFR-mutant NSCLC, while the risk of radiation pneumonia in combination of EGFR-TKI with thoracic radiotherapy is unknown. This study aims to explore the safety and efficacy of concurrent almonertinib, a new third-generation EGFR-TKI drug, with radiotherapy in local advanced EGFR-mutant NSCLC patients.

NCT ID: NCT04287894 Recruiting - Stage III NSCLC Clinical Trials

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Induction
Start date: December 28, 2018
Phase: Phase 1
Study type: Interventional

A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.